Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of therapies for metabolic and endocrine disorders. It develops metabolic diseases programs including non-steroidal selective androgen receptor modulator (SARM) currently for the treatment recovery from hip fracture surgery, thyroid receptor beta (TRb) agonist platform for lipid disorders such as hypercholesterolemia and fatty liver diseases. The company also develops rare diseases and other pipeline programs.